Cytokine-Induced Modulation of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The emergence of novel immunomodulatory cancer therapies over the last decade, above all immune checkpoint blockade, has significantly advanced tumor treatment. For colorectal cancer (CRC), a novel scoring system based on the immune cell infiltration in tumors has greatly improved disease prognostic evaluation and guidance to more specific therapy. These findings underline the relevance of tumor immunology in the future handling and therapeutic approach of malignant disease. Inflammation can either promote or suppress CRC pathogenesis and inflammatory mediators, mainly cytokines, critically determine the pro- or anti-tumorigenic signals within the tumor environment. Here, we review the current knowledge on the cytokines known to be critically involved in CRC development and illustrate their mechanisms of action. We also highlight similarities and differences between CRC patients and murine models of CRC and point out cytokines with an ambivalent role for intestinal cancer. We also identify some of the future challenges in the field that should be addressed for the development of more effective immunomodulatory therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Nevertheless, immune checkpoint blockade for CRC therapy has not yielded promising results so far (288, 289).”
BackgroundMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 7×
“As presented earlier, DNA mismatch repair-proficient CRC patients may benefit from a treatment activating the GM-CSF pathway (206), whereas IL-6 blockade may be more suitable in cases of mismatch repair-deficiency (58), i.e., for the subtype of CRC characterized by microsatellite instability (CMS1) (268).”
BackgroundInfluentialIvanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“Finally, the intestinal microbiota can influence the outcome of tumor immunotherapy, possibly by augmenting dendritic cell function and subsequent priming of anti-tumor T cells (305, 306).”
BackgroundInduction of Colonic Regulatory T Cells by Indigenous Clostridium Species
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., et al. (2011) · Science · doi:10.1126/science.1198469 · Cited by 3,752 · cited 1×
“Importantly, certain types of commensal bacteria can influence the host immune system by promoting the accumulation of Th17 or Treg in the intestinal mucosa (298, 299).”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“Finally, the intestinal microbiota can influence the outcome of tumor immunotherapy, possibly by augmenting dendritic cell function and subsequent priming of anti-tumor T cells (305, 306).”
BackgroundThe tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.007 · Cited by 2,368 · cited 1×
“Moreover, bacteria-derived butyrate induces IL-18 in the colonic epithelium (304).”
BackgroundTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
The IL-4 receptor: signaling mechanisms and biologic functions
Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J., & Paul, W. E. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.701 · Cited by 1,545 · cited 1×
“The type I IL-4 receptor complex is composed of IL-4Rα and the common gamma chain, whereas the type II IL-4 receptor consists of the IL-4Rα and IL-13Rα1 subunits (40).”
BackgroundGut microbiome development along the colorectal adenoma-carcinoma sequence
Feng, Q., Liang, S., Jia, H., Stadlmayr, A., Tang, L., Lan, Z., Zhang, D., Xia, H., Xu, X., Jie, Z., et al. (2015) · Nature Communications · doi:10.1038/ncomms7528 · Cited by 1,506 · cited 1×
“Overall changes in microbial communities have been found in the adenoma-to-carcinoma sequence of CRC, compared with healthy controls (296).”
BackgroundLlosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327 · cited 4×
“Il17ra−/− animals, which are insensitive to IL-17A and IL-17F, show reduced intestinal tumor number, size, and load during sporadic CRC (21).”
BackgroundInfluentialAtreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070
Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060
STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing
Pickert, G., Neufert, C., Leppkes, M., Zheng, Y., Wittkopf, N., Warntjen, M., Lehr, H.-A., Hirth, S., Weigmann, B., Wirtz, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082683 · Cited by 1,043
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 1×
“Soluble IL-6R, then, associates with the ubiquitously expressed glycoprotein 130 (IL-6 ST/GP130) (60).”
BackgroundIL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018 · cited 1×
“In primary CRC tissue, IL23A and IL12B transcripts are overexpressed, whereas IL12A mRNA is not upregulated (176).”
BackgroundRegulation of tumour necrosis factor signalling: live or let die
Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998
Carriere, V., Roussel, L., Ortega, N., Lacorre, D.-A., Americh, L., Aguilar, L., Bouche, G., & Girard, J.-P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606854104 · Cited by 966 · cited 1×
“This indicates that the nuclear function of IL-33 as a regulator of gene transcription (197) and its role as a soluble cytokine upon secretion (198) may promote CRC pathogenesis in this model.”
BackgroundInterleukin-23 drives innate and T cell–mediated intestinal inflammation
Hue, S., Ahern, P., Buonocore, S., Kullberg, M. C., Cua, D. J., McKenzie, B. S., Powrie, F., & Maloy, K. J. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061099 · Cited by 823
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Rokavec, M., Öner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P. K., Schwitalla, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73531 · Cited by 753 · cited 1×
“Moreover, p53 can negatively regulate IL-6 signaling (271), whereas gain-of-function mutant p53 prolongs TNF-induced NF-κB activation to increase susceptibly to CAC (272).”
BackgroundMicrobiota organization is a distinct feature of proximal colorectal cancers
Dejea, C. M., Wick, E. C., Hechenbleikner, E. M., White, J. R., Mark Welch, J. L., Rossetti, B. J., Peterson, S. N., Snesrud, E. C., Borisy, G. G., Lazarev, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406199111 · Cited by 700
Wu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z., Wang, C., Zhang, Z., Xia, W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.013 · Cited by 608
Microbiota disbiosis is associated with colorectal cancer
Gao, Z., Guo, B., Gao, R., Zhu, Q., & Qin, H. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00020 · Cited by 537
Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122308 · Cited by 529 · cited 2×
“In Helicobacter hepaticus/AOM-induced intestinal tumors, IL-22 released by ILCs supported the growth of intestinal tumors in T and B cell-deficient Rag2−/− mice (138).”
BackgroundInterleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells
Ahern, P. P., Schiering, C., Buonocore, S., McGeachy, M. J., Cua, D. J., Maloy, K. J., & Powrie, F. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.010 · Cited by 528
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Kinnebrew, M. A., Buffie, C. G., Diehl, G. E., Zenewicz, L. A., Leiner, I., Hohl, T. M., Flavell, R. A., Littman, D. R., & Pamer, E. G. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.011 · Cited by 491
Haller, D., Bode, C., Hammes, W. P., Pfeifer, A. M. A., Schiffrin, E. J., & Blum, S. (2000) · Gut · doi:10.1136/gut.47.1.79 · Cited by 466 · cited 15×
“Murine IECs produce IL-18 under steady state.”
BackgroundInfluentialRobust tumor immunity to melanoma mediated by interleukin-9–producing T cells
Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442 · cited 1×
“Although IL-9 possibly promotes lymphomagenesis (71), it can also inhibit the growth of melanoma either directly or by promoting anti-tumor immunity (72, 73).”
BackgroundMolecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention
Colussi, D., Brandi, G., Bazzoli, F., & Ricciardiello, L. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140816365 · Cited by 429 · cited 1×
“Each listed cytokine is systemically presented according to the following scheme: (1) role as a biomarker in samples of CRC patients, (2) phenotype of knockout or transgenic mice in experimental models of CRC or intestinal inflammation, (3) tissue of origin or type of the secreting cells, (4) nature of the receptor-ex…”
Salcedo, R., Worschech, A., Cardone, M., Jones, Y., Gyulai, Z., Dai, R.-M., Wang, E., Ma, W., Haines, D., O'hUigin, C., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100199 · Cited by 429 · cited 1×
“Mice deficient in Il18 or Il18r1 developed more tumors upon AOM/DSS treatment, compared with WT controls (152).”
BackgroundCorvinus, F. M., Orth, C., Moriggl, R., Tsareva, S. A., Wagner, S., Pfitzner, E. B., Baus, D., Kaufman, R., Huber, L. A., Zatloukal, K., et al. (2005) · Neoplasia · doi:10.1593/neo.04571 · Cited by 427
Zaki, M. H., Vogel, P., Body-Malapel, M., Lamkanfi, M., & Kanneganti, T.-D. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002046 · Cited by 411 · cited 1×
“Indeed, Il18−/− mice showed a more severe clinical and histopathological manifestation of colitis than WT animals upon challenge with DSS, a phenotype recapitulated in Nlrp3−/− or Casp1−/− mice (153).”
BackgroundAtreya, R., Neumann, H., Neufert, C., Waldner, M. J., Billmeier, U., Zopf, Y., Willma, M., App, C., Münster, T., Kessler, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3462 · Cited by 392 · cited 1×
“In addition to the evaluation of clinical parameters, the efficacy of such a blockade may be also directly assessed in vivo, via confocal laser endomicroscopy, as already performed in IBD patients (245).”
Self-citationSangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.059 · Cited by 320 · cited 1×
“Although administration of IL-12 as an adjuvant leads to specific immunity against tumor antigens in some patients (116), the net clinical benefit of IL-12 treatment was found to be rather moderate (117, 118).”
BackgroundIL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction
Jabri, B., & Abadie, V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3919 · Cited by 315 · cited 1×
“Cytotoxic T and NK cells represent the most important immune effectors to integrate the anti-tumorigenic function of IL-15 by activating the APO-1/FAS- or granule-mediated cytotoxic pathway (124, 126).”
BackgroundActivation of STAT3 is a marker of poor prognosis in human colorectal cancer
Kusaba, T., Nakayama, T., Yamazumi, K., Yakata, Y., Yoshizaki, A., Inoue, K., Nagayasu, T., & Sekine, I. (2006) · Oncology Reports · doi:10.3892/or.15.6.1445 · Cited by 238 · cited 1×
“org April 2016 | Volume 6 | Article 96 it is not surprising that the level of STAT3 phosphorylation in CRC patients negatively correlates with survival and is therefore indicative of a poor prognosis (62, 63).”
BackgroundCD4+CD25+ Regulatory Lymphocytes Induce Regression of Intestinal Tumors in ApcMin/+ Mice
Erdman, S. E., Sohn, J. J., Rao, V. P., Nambiar, P. R., Ge, Z., Fox, J. G., & Schauer, D. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3104 · Cited by 211 · cited 1×
“IL-10 was required in regulatory T cells (Treg) to reduce tumor burden in ApcMin/+ mice (85).”
BackgroundIL-9 and its receptor are predominantly involved in the pathogenesis of UC
Nalleweg, N., Chiriac, M. T., Podstawa, E., Lehmann, C., Rau, T. T., Atreya, R., Krauss, E., Hundorfean, G., Fichtner-Feigl, S., Hartmann, A., et al. (2015) · Gut · doi:10.1136/gutjnl-2013-305947 · Cited by 181
Self-citationWehinger, J., Gouilleux, F., Groner, B., Finke, J., Mertelsmann, R., & Maria Weber-Nordt, R. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00990-8 · Cited by 167
Nlrp3: An immune sensor of cellular stress and infection
Lamkanfi, M., & Kanneganti, T.-D. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.01.008 · Cited by 140
Cited by
Role of microbiota-derived short-chain fatty acids in cancer development and prevention
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M. R., Hosseini-Fard, S. R., Babolhavaeji, K., Khani Ali Akbari, S., Yousefimashouf, R., & Karampoor, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111619 · Cited by 394
A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer
Zaharuddin, L., Mokhtar, N. M., Muhammad Nawawi, K. N., & Raja Ali, R. A. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1047-4 · Cited by 288
Metadata
- Authors
- Mager, L. F., Wasmer, M.-H., Rau, T. T., & Krebs, P.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2016-04-19
- Volume
- 6
- Pages
- 96-96
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2340194153
- Cited by
- 216
- References
- 53
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.